4-Hydroxy-3-methoxybenzylamine hydrochloride

We are 4-Hydroxy-3-methoxybenzylamine hydrochloride CAS:7149-10-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Hydroxy-3-methoxybenzylamine hydrochloride
CAS.NO:7149-10-2
Synonyms:4-Hydroxy-3-methoxybenzylamine hydrochloride
4-(aminomethyl)-2-methoxyphenol,hydrochloride
Phenol, 4-(aminomethyl)-2-methoxy-, hydrochloride
Molecular Formula:C8H12ClNO2
Molecular Weight:189.63900
 
Physical and Chemical Properties:
Melting point:219-221ºC
Boiling point:292.9ºC
Flash point:130.9ºC
 
Specification:
Appearance:Off-white to yellow powder
Assay:≥98.0%
Loss on drying:≤0.5%
Residue on Ignition:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of capsaicin

4-Hydroxy-3-methoxybenzylamine hydrochloride


Related News: In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.3-(2-Chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one CAS:130049-82-0 Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.(R)-3-Chloro-1-phenylpropan-1-ol CAS:100306-33-0 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.185147-07-3 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.

Related Products
Product Name
trimethoxy(2-methylpropyl)silane View Details
5-Bromo-2-methylindole View Details
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane View Details
4-Aminosalicylic acid manufacturer 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide manufacturer 3-Hydroxybutanoic acid calcium salt manufacturer 1,2,3,4-Tetrahydrocarbazole manufacturer 3-Fluoro-4-methoxybenzonitrile manufacturer